VEA
FATE icon

Virtus ETF Advisers’s Fate Therapeutics FATE Stock Holding History

Virtus ETF Advisers’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-18,216
Closed -$38.6K – 442
2023
Q3 		$38.6K Sell
18,216
-1,809
-9% -$5.99K 0.02% 421
2023
Q2 		$95.3K Buy
20,025
+13,440
+204% +$74.2K 0.06% 406
2023
Q1 		$37.5K Sell
6,585
-2,528
-28% -$15.3K 0.02% 439
2022
Q4 		$92K Buy
9,113
+3,506
+63% +$65.8K 0.05% 441
2022
Q3 		$126K Buy
5,607
+41
+0.7% +$1.19K 0.05% 385
2022
Q2 		$138K Buy
5,566
+2,475
+80% +$68.3K 0.05% 333
2022
Q1 		$120K Sell
3,091
-183
-6% -$7.09K 0.05% 269
2021
Q4 		$192K Buy
3,274
+918
+39% +$52K 0.07% 223
2021
Q3 		$140K Sell
2,356
-130
-5% -$10.2K 0.06% 352
2021
Q2 		$216K Sell
2,486
-624
-20% -$50.3K 0.09% 285
2021
Q1 		$256K Buy
3,110
+49
+2% +$4.7K 0.11% 282
2020
Q4 		$278K Sell
3,061
-6,967
-69% -$433K 0.12% 249
2020
Q3 		$401K Sell
10,028
-1,361
-12% -$47.5K 0.21% 170
2020
Q2 		$391K Sell
11,389
-7,746
-40% -$231K 0.19% 205
2020
Q1 		$425K Sell
19,135
-2,782
-13% -$70.4K 0.17% 191
2019
Q4 		$429K Buy
21,917
+7,741
+55% +$123K 0.07% 234
2019
Q3 		$220K Sell
14,176
-789
-5% -$15.1K 0.04% 233
2019
Q2 		$304K Sell
14,965
-1,647
-10% -$29.7K 0.06% 206
2019
Q1 		$292K Sell
16,612
-1,728
-9% -$27.3K 0.62% 61
2018
Q4 		$235K Sell
18,340
-19,754
-52% -$275K 0.04% 168
2018
Q3 		$621K Sell
38,094
-27,979
-42% -$331K 0.06% 97
2018
Q2 		$749K Buy
+66,073
New +$728K 0.66% 71

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Virtus ETF Advisers's FATE Position: Q4 2023 in Review

Virtus ETF Advisers sold out of Fate Therapeutics (FATE) in Q4 2023, closing a stake of 18,216 shares — an estimated $38.6K sold.

Virtus ETF Advisers first reported a position in FATE in Q2 2018 and held it in 22 quarters. The position peaked at $749K in Q2 2018. 159 funds tracked by Wall St. Rank hold FATE as of Q4 2023.

  • Virtus ETF Advisers reported no remaining Fate Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Virtus ETF Advisers sold 18,216 Fate Therapeutics shares in Q4 2023, an estimated $38.6K.
  • Virtus ETF Advisers first reported a position in Fate Therapeutics in Q2 2018 and held it in 22 quarters.
  • Virtus ETF Advisers's Fate Therapeutics position peaked at $749K in Q2 2018.
  • 159 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2023.

Based on Virtus ETF Advisers's 13F filing for Q4 2023, filed 15 Feb 2024.